Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 5Phase 1 4Phase EARLY_PHASE1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Breast Neoplasms 161Neoplasms 95Prostatic Neoplasms 86Glioblastoma 76Multiple Myeloma 65Pancreatic Neoplasms 64Glioma 61Brain Neoplasms 56Lung Neoplasms 46Carcinoma, Hepatocellular 45Melanoma 43Head and Neck Neoplasms 43Recurrence 42Carcinoma, Non-Small-Cell Lung 41Leukemia, Myeloid, Acute 40Colorectal Neoplasms 39Squamous Cell Carcinoma of Head and Neck 35Ovarian Neoplasms 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 31Neoplasm Metastasis 29Lymphoma, Non-Hodgkin 29Lymphoma 28Carcinoma, Renal Cell 28Polycystic Ovary Syndrome 27Stomach Neoplasms 24Hematologic Neoplasms 23Lymphoma, B-Cell 22Sarcoma 21Endometrial Neoplasms 20Uterine Cervical Neoplasms 19

Interventions

nilotinib 1Ranibizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Neurofibroma × Clear all
NCT01275586 2017-04-12

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Indiana University

Phase EARLY_PHASE1 Completed
6 enrolled 7 charts
CNS

Neurofibroma, Neurofibromatoses, Neurofibroma, Plexiform

NCT00657202 2016-07-07

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Massachusetts General Hospital

Phase EARLY_PHASE1 Completed
11 enrolled
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡